Addex Therapeutics (NASDAQ:ADXN) Stock Rating Reaffirmed by HC Wainwright

Addex Therapeutics (NASDAQ:ADXN)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $30.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 219.15% from the company’s current price.

Addex Therapeutics Stock Performance

ADXN stock opened at $9.40 on Wednesday. Addex Therapeutics has a fifty-two week low of $5.00 and a fifty-two week high of $27.90. The company has a market capitalization of $9.96 million, a price-to-earnings ratio of -0.54 and a beta of 1.79. The business’s 50 day moving average price is $9.14 and its two-hundred day moving average price is $10.58.

Addex Therapeutics (NASDAQ:ADXN) last posted its quarterly earnings data on Monday, September 30th. The company reported ($1.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($1.70). The company had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.26 million. Addex Therapeutics had a negative net margin of 818.50% and a negative return on equity of 364.24%. Sell-side analysts forecast that Addex Therapeutics will post -0.36 earnings per share for the current year.

Addex Therapeutics Company Profile

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.